Replimune Group, Inc.'s RP1 has failed at the FDA twice, but Makary's resignation keeps a resubmission possible. REPL's cash runway stands at under a year; workforce cuts and RP1 discontinuation are ...

This project is a proof-of-concept that runs a JavaScript engine inside a web browser by compiling it to WebAssembly. The engine is Goja — a pure-Go implementation of ECMAScript 5.1 — and the ...

Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...

Fintel reports that on November 3, 2025, BMO Capital upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underperform to Market Perform. As of October 30, 2025, the average one-year price ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Note, this article deals with client-side JavaScript. For a client and server-side JavaScript ...

Robbie has been an avid gamer for well over 20 years. During that time, he's watched countless franchises rise and fall. He's a big RPG fan but dabbles in a little bit of everything. Writing about ...